Can we Improve Mortality Prediction in Patients With Sepsis in the Emergency Department

Iuliu Hatieganu University of Medicine and Pharmacy

Status

Completed

Conditions

Sepsis Syndrome

Emergency Department

Biomarker

Treatments

Diagnostic Test: ELISA Sepsis Biomarkers dosage

Study type

Observational

Funder types

Other

Identifiers

NCT06338111

2461

Details and patient eligibility

About

This study aims to identify the prognostic role of procalcitonin (PCT), soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1), the soluble form of the urokinase plasminogen activator receptor (suPAR), highly sensitive C-reactive protein (hs-CRP), Interleukin-6 (IL-6), and azurocidin 1 (AZU1) in 28-day mortality for patients with sepsis in Emergency Department.

Full description

The levels of the specified biomarkers were measured upon patient arrival at the Emergency Department (ED) and analyzed their correlation with 28-day mortality. The values of these biomarkers were monitored over the initial three days following admission to the ED, aiming to explore their potential in guiding the de-escalation of antibiotic treatment. Considering their prognostic significance, the main goal is to develop a novel scoring system tailored for use in the emergency department setting.

Enrollment

67 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Sepsis 3 Criteria

Exclusion criteria

individuals aged under 18 or above 90
pregnant women
individuals in custody or deprived of their liberty
patients with associated pathologies such as severe trauma
other types of shocks
acute stroke
burns
pancreatitis myocardial infarction, pulmonary edema, status asthmatics, convulsions, drug overdose, those requiring emergency surgery
terminal stage of neoplastic disease